Progress Vs. Price: Evaluating Tempus AI's High Valuation Thesis

Tempus AI has surged ~75% since August, but current valuations (~15x EV/forward revenue) are unsustainable for its hybrid ...

Tempus Screens Overvalued, Yet Data And Services Optionality Keeps It In Play

Tempus AI, Inc. remains a Hold due to valuation & lack of profitability; shows strong revenue growth & diversification. Learn ...
Precision Medicine Online

Tempus AI Awarded $60.5M Contract to Support ARPA-H Precision Cancer Therapy Program

The company will provide CRO and testing services for the ADAPT program to guide the project's clinical trials.
Standard-Journal

Tempus Selected by ARPA-H to Provide CRO and Testing Services for the ADAPT Program, Advancing Precision Cancer Therapy

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it has been selected by the Advanced Research Projects Agency for Health ...